Patent classifications
A61K31/695
CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS
Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.
CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS
Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.
COMPOSITIONS COMPRISING ORGANO-SILANOL COMPOUNDS, AND APPLICATIONS
A composition comprising stabilised organo-silanol compounds, said composition comprising two different organo-silanols and an organo-silanol(s) stabilising/complexing agent.
COMPOSITIONS COMPRISING ORGANO-SILANOL COMPOUNDS, AND APPLICATIONS
A composition comprising stabilised organo-silanol compounds, said composition comprising two different organo-silanols and an organo-silanol(s) stabilising/complexing agent.
Silylalkyloxyaryl compounds and methods for treating cancer
Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.
Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections
The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections
The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
Silanol based therapeutic payloads
Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
Silanol based therapeutic payloads
Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND
Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof:
##STR00001##
wherein L.sup.1 is an optionally substituted C.sub.1-6 alkylene group or the like, L.sup.2 is a single bond or the like, L.sup.3 is a single bond or the like, R.sup.1, R.sup.2, and R.sup.3 are each independently an optionally substituted C.sub.1-4 alkyl group or the like, R.sup.4 is a hydrogen atom or the like, and R.sup.5 is a hydrogen atom or the like.